Clinical Trials Logo

Prostatic Neoplasms clinical trials

View clinical trials related to Prostatic Neoplasms.

Filter by:
  • Available  
  • Page 1

NCT ID: NCT06033001 Available - Clinical trials for Castration-Resistant Prostatic Cancer

Expanded Access Treatment With [Lu-177]-PNT2002 for Adult Patients With Prostate-Specific Membrane Antigen (PSMA)-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Start date: n/a
Phase:
Study type: Expanded Access

The purpose of this program is to provide access to [Lu-177]-PNT2002 to patients who have been diagnosed with prostate-specific membrane antigen (PMSA)-positive castration-resistant prostate cancer (mCRPC). Patients must have received at least 1 prior androgen pathway inhibitor (ARPI) and cannot be treated by currently available drugs or clinical trials. In this program participants will be administered [Lu-177]-PNT2002 intravenously every 8 weeks (about every 2 months) for 4 cycles, or 8 months of total treatment. During treatment, participants will be monitored with routine laboratory tests such as: - Hematology blood tests - Clinical Chemistry blood tests - Testosterone/Prostate Antigen levels blood test - Vital signs - Imaging - ECG

NCT ID: NCT05650476 Available - Clinical trials for Metastatic Castration-Resistant Prostate Cancer

Pre-approval Single-patient Expanded Access for Talazoparib (PF-06944076)

Start date: n/a
Phase:
Study type: Expanded Access

Provide pre-approval single-patient Expanded Access (Compassionate Use) of talazoparib for patients with metastatic castration-resistant prostate cancer.

NCT ID: NCT04337099 Available - Prostate Cancer Clinical Trials

A Single Patient Compassionate Use of MBM-02 (Tempol) for the Treatment of Prostate Cancer

Start date: n/a
Phase:
Study type: Expanded Access

A single patient compassionate use clinical trial for the use of MBM-02 (TEMPOL) for the treatment of prostate cancer. The single patient will be exposed to orally administered TEMPOL for up to 12 months at a maximum total daily dose of 800mg.